# Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)

> **NCT01114568** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ertugliflozin 10 mg tablet
- **DRUG:** Ertugliflozin OC Fast
- **DRUG:** Ertugliflozin OC Slow

## Key facts

- **NCT ID:** NCT01114568
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01114568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01114568, "Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01114568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*